Double Bond Pharmaceutical (DBP) Q4 2024 earnings summary

Executive summary

• Focused on advancing lead product SI-053, achieving significant development milestones and preparing for clinical phase entry, with clinical studies transitioned to the new CTIS system for regulatory compliance.

• Optimized manufacturing processes and secured patents for SI-053 on all strategic markets until 2036, with new applications in progress.

• Amended partnership with Vivo Biopharma, retaining rights for key territories and securing milestone payments, royalties, and equity stake.

Financial highlights

• Q4 2024 total revenue: 0.2 MSEK (0.3 MSEK Q4 2023); full year 2024: 1.1 MSEK (1.4 MSEK 2023).

• Q4 2024 operating result: -1.9 MSEK (-3.2 MSEK Q4 2023); full year: -7.8 MSEK (-13.4 MSEK 2023).

• Q4 2024 net result: -5.0 MSEK (-7.1 MSEK Q4 2023); full year: -13.2 MSEK (-17.3 MSEK 2023).

• EPS for Q4: -0.05 (-0.08 Q4 2023); full year: -0.13 (-0.19 2023).

• Cash at year-end: 3.8 MSEK (3.8 MSEK 2023).

Outlook and guidance

• Existing liquidity expected to last until Q3 2025; future funding anticipated from EU grants, SI-053 sales, licensing, and/or new share issues.

• No dividend proposed for 2024; future dividends remain an ambition.